Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

mRNA COVID Vaccine Dosing Intervals May Be Extended To Mitigate Myocarditis Risk

Executive Summary

While data suggests higher risk of myocarditis in young males receiving Moderna’s vaccine, US CDC advisory committee did not consider preferential recommendation. ACIP voted to recommend Spikevax for those 18 years and older following full FDA approval.

You may also be interested in...



All Myocarditis, Pericarditis Cases With COVID-19 Vaccines Now Must Be Reported To VAERS

The change to three vaccine emergency use authorizations was made quietly, most recently for the Novavax vaccine.

COVID-19 Vaccine Dosing Interval Studies Advocated By US FDA, ACIP

FDA’s Doran Fink and CDC’s ACIP members say vaccine manufacturers could conduct a study to determine whether longer intervals between doses would provide greater effectiveness and longer durability. Right now, they are relying on international data.

Moderna’s Vaccine Gets Panel Nod In Adolescents, Older Children; Committee Already Eyes Booster

US FDA advisory committee members debate how a third dose, or booster, of the COVID vaccine should fit into the mix of an EUA expansion for the 12-17 and 6-11 groups; Moderna expects to have immunogenicity and safety data on booster doses in both of age groups by mid-July.

Related Content

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel